BACHMANN Andre Suit

Professor, Associate Chair for Research

400 Monroe Ave NW
(616) 234-2841
Email
PubMed

Dr. Bachmann is a tenured Full Professor of Pediatrics at Michigan State University (MSU), College of Human Medicine (CHM) and serves as Associate Chair for Research in the Department of Pediatrics and Human Development. For the past 27 years, his research has primarily focused on ODC/polyamines and drug development in oncology. He is best known for his preclinical work with ODC inhibitor DFMO (Eflornithine) (e.g., Oncogene, 2005; Cancer Res, 2008; Biochem J, 2018; J Biol Chem, 2018), which led to the treatment of patients with relapsed/refractory neuroblastoma in phase I/II studies (PLoS One, 2015). He is credited for moving DFMO from “bench to bedside” and received the Inaugural Weinman Innovator Award for Translational Research in 2010. Since the inception of his pioneering work in 2001, DFMO has entered several independent multi-center neuroblastoma phase I/II clinical studies at many Children’s hospitals across the United States and abroad, through clinical trial consortia including the Children’s Oncology Group (COG) (randomized phase II trial ANBL1821), NANT, and Beat Childhood Cancer (formerly NMTRC).


Dr. Bachmann collaborates with medical geneticist Dr. Caleb Bupp, MD and pediatric ICU physician Dr. Surender Rajasekaran, MD at the Helen DeVos Children’s Hospital. Together, they defined a new ODC1-gene linked gain-of-function disorder, now referred to as Bachmann-Bupp Syndrome (Am J Med Genet, 2018; Biochem J, 2019). In 2019, they launched the worldwide first FDA-approved single patient trial to treat this ODC1 patient with DFMO. He is the Scientific Director of the newly launched “International Center of Excellence for Polyamine Disorders” in Grand Rapids, Michigan, USA.


Further of interest to the Bachmann lab are the discovery and development of natural products-based drugs. In collaboration with colleagues in Europe, Dr. Bachmann discovered the Syrbactin class of proteasome inhibitors (Nature, 2008), a natural product for which he holds several patents. TIR-199 is the best-in-class synthetic lead compound (J Biol Chem, 2016) currently in preclinical development at Hibiskus Biopharma, Inc., a company that Dr. Bachmann founded with Dr. Michael Pirrung (UC Riverside).



bachmann lab photo

Education & Training


  • MS, Microbiology, University of Zürich/ETH Zürich, Switzerland, 1994

  • PhD, Biology, University of Zürich, Switzerland, 1998

  • Postdoctoral Fellow, Molecular Oncology & Virology, University of Zürich, Switzerland, 1998-1999

Selected Grants


Active
  • R21, National Cancer Institute Grant (NCI), NIH, 2018-2020

  • Spectrum Health-MSU Alliance Cooperation Grant, 2019-2022

  • St. Baldrick's Foundation Research Grand, 2018-2020

  • Spectrum Health SHORA Grant, 2017-2020

  • Spectrum Health MODS Grand, 2017-2020
Past Awards (Selected)
  • R01, National Cancer Institute (NCI), NIH

  • Wipe Out Kids Cancer (WOKC) Grant

  • ARRA/R01 Grant, National Cancer Institute (NCI), NIH

  • CURE/R01 Grant, National Cancer Institute (NCI), NIH

  • R43, National Institute of Allergy and Infectious Disease (NIAID), NIH

  • Hawaii Community Foundation (HCF)

  • Magic Water Foundation

  • Weinman Foundation

Selected Peer-Reviewed Publications


  • Oncogene, 2005, 24(36):5606-18

  • Clinical Cancer Research, 2007, 13(21):6312-9

  • Cancer Research, 2008, 68(23):9825-31

  • Nature, 2008, 452(7188):755-8

  • Molecular Cancer Therapeutics, 2009, 8(7):2067-75

  • PNAS, 2009, 106(16):6507-12

  • International Journal of Cancer, 2010, 126(9):2012-24

  • Cancer Science, 2010, 101(7):1624-31

  • Biochemistry, 2012, 51(34):6880-8

  • Journal of Molecular Biology, 2014, 426(2):332-46

  • Cellular Oncology, 2014, 37(6):387-98

  • PLoS One, 2015, 10(5):e0127246

  • BMC Cancer, 2015, 15:477

  • Journal of Biological Chemistry, 2016, 291:8350-62

  • PLoS One, 2017, 12(12):e0189044

  • Bioorganic & Medicinal Chemistry, 2018, 26(2):401-12

  • Biochemical Journal, 2018, 475(2):531-45

  • Journal of Biological Chemistry, 2018, 293: 18757-69

  • American Journal of Medical Genetics A,, 2018, 176:2548-53

  • Biochemical Pharmacology, 2019, 162:237-49

  • Biochemical Journal, 2019, 476:2047-57

Awards & Honors


  • Swiss National Science Foundation Award, 1994

  • Siemens National Mentor Award, 2007

  • Inaugural Weinman Award for Translational Research, 2010

  • Vice Chair (2019) and Chair (2021), Gordon Research Conference on Polyamines

Lab Directory

André S. Bachmann, PhD
André S. Bachmann, PhD
Professor; Associate Chair for Research

Chad Schultz, BS
Chad Schultz, BS
Research Assistant II
This email address is being protected from spambots. You need JavaScript enabled to view it.